Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Speedy Approval Of Roche's Zelboraf Puts Pressure On Bristol's Yervoy

This article was originally published in The Pink Sheet Daily

Executive Summary

Personalized melanoma medicine vemurafenib set to sell for $9,400 a month, says Genentech. Genetic testing should be available right away.
Advertisement

Related Content

Delcath’s Melblez Chemosaturation System To Face ODAC Scrutiny
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Preparing For A Pricing Shift: Roche Admits Cost Is An Issue In Oncology And Beyond
Front-Line Of Melanoma Market Could Be Marketing Battle
Bristol/Roche Finally Start Combination Melanoma Trial
Roche's Vemurafenib Filed With Companion Diagnostic In Tow

Topics

Advertisement
UsernamePublicRestriction

Register

PS072651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel